Full Press Release Details
Leap Therapeutics Announces Closing of $58.88
Million Private Placement in Cash
Led by Winklevoss Capital to
Initiate a Digital Asset Treasury Strategy
Cambridge, MA - October 9, 2025 -
Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today
announced that it has closed its previously announced private placement led by Winklevoss Capital raising $58,888,888 in cash to
initiate a digital asset treasury strategy. At the closing of the transaction, Leap issued (i) 15,212,311 shares of common stock
(the "Shares"), (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of
80,768,504 shares of common stock, and (ii) warrants to purchase an additional 71,985,605 shares of common stock at an exercise
price of $0.5335 per share (the "Warrants" and together with the Shares and the Pre-Funded Warrants, the
Winklevoss Capital will provide both capital and
strategic support to help Leap structure and execute its digital asset treasury strategy. Leveraging the expertise of Winklevoss Capital,
Leap aims to build long-term shareholder value through participation in digital assets. A portion of the capital will be used to
continue development of Leap's therapeutic programs, including FL-501 and sirexatamab, which has recently completed a randomized
controlled Phase 2 trial in patients with colorectal cancer that is being presented in a Mini Oral Session at the European Society for
Medical Oncology (ESMO) Congress 2025 on October 19 in Berlin, Germany.
Pursuant to a lead investor agreement, Leap has
increased the size of its Board of Directors to 12 members, and Winklevoss Capital will have the right to nominate two individuals to
Leap's Board of Directors, one of whom shall also be the chairperson of the Board.
Leap expects to release additional updates regarding its treasury activities
Parcrest acted as the placement agent in connection with the financing.
Morgan, Lewis & Bockius LLP acted as legal advisor to Leap, and
Cooley LLP acted as legal advisor to Winklevoss Capital.
The offer and sale of
the foregoing securities is being made in a private placement in reliance on an exemption from the registration requirement of the Securities
Act of 1933, as amended (the "Securities Act"), pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D promulgated
thereunder, and applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold
in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirement of the Securities Act and such applicable state securities laws. Concurrently with the execution of the securities purchase
agreements, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file
a registration statement with the Securities and Exchange Commission (the "SEC") registering the resale by the purchasers
participating in the offering of the Shares and the shares of common stock underlying the Pre-Funded Warrants and
the Warrants. Any offering of the Company's common stock under the resale registration statement will only be made by means
This press release shall
not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.
The private placement
was conducted in accordance with applicable Nasdaq rules and was priced to satisfy the "Minimum Price" requirement (as defined
in the Nasdaq rules).
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on
developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab (DKN-01), a humanized monoclonal antibody targeting
the Dickkopf-1 (DKK1) protein and FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15)
protein. Leap is initiating a digital asset treasury strategy following a $58.88 million investment led by Winklevoss Capital. For more
information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available
via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
About Winklevoss Capital
Winklevoss Capital is an investment firm founded in 2012 by Cameron
and Tyler Winklevoss that invests in frontier technologies.
Forward Looking Statements
This press release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect,"
"plan," "could," "may," "will," "believe," "estimate," "forecast,"
"goal," "project," and other words of similar meaning. These forward-looking statements address various matters
including statements relating to the anticipated benefits and timing of the completion of the proposed offering and related transactions,
the intended use of proceeds from the offering, the assets to be held by the Company, the expected future market, price and liquidity
of the digital assets the Company acquires, the macro and political conditions surrounding digital assets, the Company's plan for
value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest
of other corporations in similar business strategies, technological and market trends, future financial condition and performance and
the expected financial impacts of the proposed transactions described herein. Each forward-looking statement contained in this press release
is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.
Applicable risks and uncertainties include, among others, the risk that the proposed transactions described herein may not be completed
in a timely manner or at all; failure to realize the anticipated benefits of the transactions and the proposed digital asset treasury
strategy; changes in business, market, financial, political and regulatory conditions; risks relating to the Company's operations
and business, including the highly volatile nature of the price of cryptocurrencies; the risk that the price of the Company's common
stock may be highly correlated to the price of the digital assets that it holds; risks related to increased competition in the industries
in which the Company does and will operate; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding
digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes, as well as those risks and
uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in
this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these
President & Chief Executive Officer
Leap Therapeutics, Inc.